Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2025)
Allogene Therapeutics (ALLO) has disclosed Receivables - Other for 6 consecutive years, with $23.5 million as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 13.03% to $23.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.5 million through Dec 2025, up 13.03% year-over-year, with the annual reading at $23.5 million for FY2025, 13.03% up from the prior year.
- Receivables - Other hit $23.5 million in Q4 2025 for Allogene Therapeutics, roughly flat from $23.5 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $23.5 million in Q2 2025 to a low of $1.2 million in Q1 2023.
- Historically, Receivables - Other has averaged $12.8 million across 5 years, with a median of $9.8 million in 2022.
- Biggest five-year swings in Receivables - Other: soared 142.86% in 2022 and later crashed 87.23% in 2023.
- Year by year, Receivables - Other stood at $4.1 million in 2021, then crashed by 63.41% to $1.5 million in 2022, then fell by 20.0% to $1.2 million in 2023, then skyrocketed by 1631.08% to $20.8 million in 2024, then grew by 13.03% to $23.5 million in 2025.
- Business Quant data shows Receivables - Other for ALLO at $23.5 million in Q4 2025, $23.5 million in Q3 2025, and $23.5 million in Q2 2025.